Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be
beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for …

Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that
have been used for decades to lower cholesterol and to prevent or treat cardiovascular …

Purpose Breast cancer is the most common cancer in females and the leading cause of
death worldwide. The effects of statins on breast cancer prognosis have long been …

Purpose A growing body of evidence suggests that statins may have chemopreventive
potential against breast cancer. Laboratory studies demonstrate that statins induce …

Background A sizeable body of evidence suggests that statins can cease breast cancer
progression and prevent breast cancer recurrence. The latest studies have, however, not …

Emerging evidence suggests that statins' may decrease the risk of cancers. However,
available evidence on breast cancer is conflicting. We, therefore, examined the association …

Much preclinical and epidemiological evidence supports the anticancer effects of statins.
Epidemiological evidence does not suggest an association between statin use and reduced …

Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl
coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed …

Background Accumulating evidence suggests that statins affect diseases other than
cardiovascular disease, including cancer, and that these effects may depend on the lipid …

Recent studies have suggested that statins, an established drug group in the prevention of
cardiovascular mortality, could delay or prevent breast cancer recurrence but the effect on …